American Glaucoma Society Meeting
American Glaucoma Society Meeting
March 06, 2017
1 min read
Save

Reduced IOP with CyPass plus phaco maintained at 2 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CORONADO, Calif. — IOP reduction was sustained at 2 years in patients with mild to moderate primary open-angle glaucoma who underwent CyPass micro-stent implantation at the same time as cataract surgery in the COMPASS trial, Quang H. Nguyen, MD, and colleagues reported in a poster presented at the American Glaucoma Society meeting.

In the randomized intervention trial, 374 patients underwent the combination of phacoemulsification plus CyPass micro-stent (Alcon) implantation, with 61.2% of those patients maintaining mean IOP between 6 mm Hg and 18 mm Hg at 2 years. Of the 131 patients who underwent phacoemulsification only, 43.5% maintained that mean value. The difference was statistically significant (P = .0005).

Patients were included who had unmedicated diurnal IOP of 21 mm Hg to 33 mm Hg, which was at least 3 mm Hg higher than the medicated IOP measured at the screening visit.

Endpoints at 24 months were proportion of subjects with a 20% or greater reduction in unmedicated diurnal IOP from baseline, mean reduction of unmedicated diurnal IOP from baseline and proportion of eyes with mean unmedicated diurnal IOP between 6 mm Hg and 18 mm Hg.

Postoperative adverse ocular events were comparable in both groups, including secondary surgical interventions.

The COMPASS study “is the first study with 2-year follow-up, baseline and terminal washout to measure true IOP-lowering effect of CyPass when used in conjunction with cataract surgery,” the authors wrote. – by Patricia Nale, ELS

Reference:

Nguyen QH, et al. Minimally invasive supraciliary microstent for IOP control in combined POAG-cataract surgery: 2-year COMPASS trial results. Poster presented at: American Glaucoma Society annual meeting; March 2-5, 2017; Coronado, Calif.

Disclosure: Nguyen reports he is a consultant and speaker for Alcon.